

AMENDMENTS

IN THE SPECIFICATION:

Please replace the first line of page 1 (i.e., the title) with the following title:

Polynucleotides Encoding a CD20/IgE-Receptor Like Molecule and Uses Thereof

IN THE CLAIMS:

Please cancel claims 2, 3, 9, 11-50, 56-69, and 71.

Please amend claims 1, 4, 8, 10, 51, 52, 53, 54, and 70 and new claim 72 as follows:

1. (Amended) An isolated nucleic acid comprising a nucleotide sequence selected from the group consisting of:

(a) a nucleotide sequence set forth in SEQ ID NO: 1;

Q1 (b) a nucleotide sequence encoding a polypeptide comprising an amino acid sequence as set forth in SEQ ID NO: 2; and

(c) a nucleotide sequence fully complementary to (a) or (b).

Q2 4. (Amended) A vector comprising the nucleic acid of claim 1.

Q3 8. (Amended) A process of producing a CD20/IgE-receptor like polypeptide comprising culturing the host cell of claim 5 under suitable conditions to express a CD20/IgE-receptor like polypeptide encoded by the nucleic acid.

Q4 10. (Amended) The process of claim 8, wherein the vector further comprises a heterologous promoter operatively linked to the nucleotide sequence encoding the CD20/IgE-receptor like polypeptide.

51. (Amended) A composition comprising a nucleic acid of claim 1 and a pharmaceutically acceptable formulating agent.

Q5 52. (Amended) A composition of claim 51 wherein said nucleic acid is contained in a viral vector.